Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 02

245P - Impact of regular intensive imaging surveillance on survival after recurrence in patients with early breast cancer; a propensity score matching study

Date

10 Sep 2022

Session

Poster session 02

Topics

Staging and Imaging

Tumour Site

Breast Cancer

Presenters

Chan Sub Park

Citation

Annals of Oncology (2022) 33 (suppl_7): S88-S121. 10.1016/annonc/annonc1040

Authors

C.S. Park1, H. Kim1, M.K. Seong1, I.C. Park2, H.J. Kim1, S.W. Kim1, J.H. Lee1, J. Kim3, G. Gwak3

Author affiliations

  • 1 Surgery, Korea Cancer Center Hospital, 01812 - Seoul/KR
  • 2 Fusion Radiology Research, Korea institute of radiological & medical science, 01812 - Seoul/KR
  • 3 Surgery, Sanggye Paik Hospital - Inje University College of Medicine, 139-707 - Seoul/KR

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 245P

Background

Current major guidelines recommend only mammography as routine imaging surveillance for asymptomatic breast cancer survivors after curative treatment. However, as improving of the treatment for patients with metastatic disease, we assume that the detection of metastases in an asymptomatic status may improve the survival. Therefore, we investigated impact of intensive imaging surveillance on survival in breast cancer patients who developed distant metastasis as a first event.

Methods

We retrospectively analyzed the medical records from two institutions. The data included metastatic breast cancer patients as a first event after curative surgery from 1999 to 2021. Patients were classified into three groups (group I, distant metastasis was detected by symptoms without any regular surveillance; group II, by symptom between routine intensive imaging surveillance; group III, by regular intensive imaging surveillance without symptoms). Propensity score matched (PSM) analysis was performed with following covariates: age, subtypes, time interval from the diagnosis to metastasis, pathologic stage. Overall survival after distant metastasis (dmOS) was defined as the period from the first date of diagnosis with distant metastasis to the date of death of any cause or to the date of last follow-up.

Results

A total of 921 patients were eligible for this study. The median follow-up period was 62 months (range 6-266months). Of these patients, group I, II, and III contained 63 (6.8%), 234 (25.4%), and 624 (67.8%) patients. The median dmOS of group I, II, and III was 23, 12, and 26 months. The dmOS of group II showed significantly worse than group I (p=0.005) and group III (p<0.001). After PMS by the ratio of 1:1:1, 63 patients were remained in each group. The median dmOS of group I, II, and III was 23, 23, and 32 months. The better dmOS of group III than group I or II was found. (group I versus group III, p<0.001; group II versus group III, p=0.001).

Conclusions

Patients whose distant metastasis was detected on routine intensive imaging surveillance in asymptomatic status have significantly better outcomes than the patients whose distant metastasis was detected by symptoms.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.